Mitochondrial and Immunoallergic Injury Increase Risk of Positive Drug Rechallenge After Drug-Induced Liver Injury: A Systematic Review
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
In prospective studies, drug rechallenge following drug-induced liver injury (DILI) is associated with up to 13% mortality,1 whereas retrospective case series report a 2% mortality rate across a broad range of drugs2 and a 51% mortality rate with halothane rechallenge.3 However, risk factors for severe liver injury with rechallenge are poorly characterized.1-4 Clinical outcomes following drug rechallenge appear to vary markedly by drug,2, 3, 5-7 suggesting that rechallenge risk may be related to drug-specific mechanisms of injury. Drug rechallenge is rarely deliberately performed due to potential fatalities.4 However, drug rechallenge may be considered in life-threatening disease, when no other treatments are available with informed consent and close follow-up. Because limited data on drug rechallenge are available, additional data are needed to enhance clinical decision making. The aim of this systematic analysis is to examine clinical outcomes and mechanisms of liver injury that may influence a drug's potential for serious or fatal injury following rechallenge. When compared with the initial liver injury, rechallenge injury occurs more rapidly (generally after days or weeks, but sometimes within hours of rechallenge).2 Rechallenge events commonly result in jaundice (64%), hospitalization (52%), or allergic/hypersensitivity features (39%).4 Most rechallenge events are inadvertent and hence preventable if initial DILI is accurately identified and clearly communicated to the patient. DILI results from the cumulative effects of oxidative stress, reactive metabolites, immune injury from protein adducts, inhibition or disruption of transporters or drug metabolism, mitochondrial impairment,8 loss of ion gradients and adenosine triphosphate (ATP), and activation of programmed cell death or necrosis.9 Intraindividual and environmental factors, inflammatory mediators, and glutathione stores further modulate the outcome of DILI. For example, diabetes increases the risk of acute liver failure,10 which may be related to diminished mitochondrial function.8, 10, 11 In addition, approximately 1 in 8,000 adults harbor inherited pathogenic mitochondrial DNA mutations.12 Most drugs withdrawn from the market are mitochondrial toxicants, as are more than half of marketed drugs with black box warnings for hepatotoxicity or cardiotoxicity.13 Mitochondria are the key cellular energy source, supplying more than 90% of cellular ATP.13 Therefore, drug-induced mitochondrial impairment directly affects hepatocyte viability.8 Mitochondrial energy is largely generated by fatty acid oxidation; mitochondrial respiration also generates reactive oxygen species.13 Drugs or metabolites that inhibit the mitochondrial electron transport chain increase reactive oxygen species and can trigger the mitochondrial permeability transition (depleting the mitochondrial membrane potential difference), resulting in cell death.8, 13 Nucleoside analogues for treatment of human immunodeficiency virus inhibit mitochondrial DNA synthesis in a concentration-dependent fashion, resulting in decreased mitochondrial respiration and ATP and increased lactate.13 Drugs that are lipophilic and cationic (such as tacrine) accumulate in mitochondria and increase the risk of mitochondrial toxicity.13 Cell death occurs when a critical number of a hepatocyte's mitochondria are disabled.8 Upon withdrawal of mitochondrial toxicants, mitochondria can successfully regenerate over one to several weeks.14, 15 The likelihood of DILI is significantly increased in patients exhibiting polymorphisms of mitochondrial DNA polymerase gamma,16, 17 superoxide dismutase 2 (which scavenges mitochondrial superoxide),18 or specific human leukocyte antigen (HLA) markers associated with immunoallergic injury.19-23 Immunoallergic injury or hypersensitivity is associated with fever, rash, eosinophilia, and antidrug antibodies and occurs rapidly on rechallenge (sometimes within hours). Immunoallergic injury is initiated when a reactive drug or metabolite binds to intracellular proteins and generates a hapten, which is taken up by antigen-presenting cells and presented with major histocompatibility complex to helper T cells, and further activated by a danger signal of cytokines, such as high mobility group box 1 or other markers of necrosis or inflammation, to stimulate an immune response.24 Among the potential mechanisms of hepatotoxicity, concomitant mitochondrial impairment and immunoallergic injury appear most likely associated with fatal or positive rechallenge. Drug-specific rechallenge outcomes were systematically reviewed to examine the hypothesis that drug-related mitochondrial impairment and/or immunoallergic injury may particularly increase the risk of positive rechallenge or fatality and to further assess other rechallenge risk factors. With mitochondrial injury, rechallenge within several weeks of the primary DILI would be expected to greatly increase the risk of positive or fatal recha
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Mitochondrial dysfunction in Nash: causes, consequences and possible means to prevent it
Begriche, K., Igoudjil, A., Pessayre, D., & Fromenty, B. (2006) · Mitochondrion · doi:10.1016/j.mito.2005.10.004 · Cited by 753
Toxicity of statins on rat skeletal muscle mitochondria
Kaufmann, P., Török, M., Zahno, A., Waldhauser, K. M., Brecht, K., & Krähenbühl, S. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6235-z · Cited by 263
Strategies to reduce late-stage drug attrition due to mitochondrial toxicity
Dykens, J. A., Marroquin, L. D., & Will, Y. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.2.161 · Cited by 95 · cited 4×
“Mitochondrial dysfunction can be caused by a diverse array of drugs, including antibiotics, antiretrovirals, antidepressants, antianginals, nonsteroidal anti-inflammatory agents, anticonvulsants, anesthetics, antiarrhythmics, and oncology agents.(37,47) In drugs initiating mitochondrial dysfunction, liver injury devel…”
BackgroundInfluential
Cited by
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management
Ramappa, V., & Aithal, G. P. (2013) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2012.12.001 · Cited by 508
Mechanisms of drug-induced liver injury: from bedside to bench
Tujios, S., & Fontana, R. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.22 · Cited by 277
A prospective nationwide study of drug-induced liver injury in Korea
Suk, K. T., Kim, D. J., Kim, C. H., Park, S. H., Yoon, J. H., Kim, Y. S., Baik, G. H., Kim, J. B., Kweon, Y. O., Kim, B. I., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.138 · Cited by 221
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
Drug induced liver injury and its relationship to autoimmune hepatitis
Weiler-Normann, C., & Schramm, C. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.024 · Cited by 92
Drug rechallenge following drug-induced liver injury
Hunt, C. M., Papay, J. I., Stanulovic, V., & Regev, A. (2017) · Hepatology · doi:10.1002/hep.29152 · Cited by 72
Self-citation
Metadata
- Authors
- Hunt, C. M.
- Venue
- Hepatology
- Published
- 2010-12
- Volume
- 52
- Issue
- 6
- Pages
- 2216-2222
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1981566552
- Cited by
- 39
- References
- 6
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.